Literature DB >> 9365838

BCR/ABL-negative chronic myeloid leukemia with ETV6/ABL fusion.

P Andreasson1, B Johansson, M Carlsson, I Jarlsfelt, T Fioretos, F Mitelman, M Höglund.   

Abstract

A BCR/ABL-negative chronic myeloid leukemia (CML) with t(12;14) (p12;q11-13) as the sole chromosomal abnormality was investigated by fluorescence in situ hybridization (FISH), which disclosed a cryptic insertion of ETV6 (previously called TEL), located at 12p12, into ABL at chromosome band 9q34. ETV6/ABL fusion was confirmed by RT-PCR, revealing that the first five exons of ETV6 were fused in frame with ABL at exon 2. Wild-type ETV6 was expressed, in accordance with the FISH results showing no deletion of the second ETV6 allele. ETV6/ABL chimeric transcripts have previously been reported in acute leukemias, but never before in CML. The present case suggests that ETV6/ABL positivity may constitute a new genetic subgroup of BCR-negative CML.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365838

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  12 in total

1.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.

Authors:  Fabiana Perna; Omar Abdel-Wahab; Ross L Levine; Suresh C Jhanwar; Kazunori Imada; Stephen D Nimer
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

Review 3.  [The 8p11 myeloproliferative syndrome].

Authors:  A Reither; R Hehlmann; J M Goldman; N C Cross
Journal:  Med Klin (Munich)       Date:  1999-04-15

Review 4.  Mechanisms of transformation by the BCR/ABL oncogene.

Authors:  M Sattler; J D Griffin
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

6.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

7.  Characterization of leukemias with ETV6-ABL1 fusion.

Authors:  Marketa Zaliova; Anthony V Moorman; Giovanni Cazzaniga; Martin Stanulla; Richard C Harvey; Kathryn G Roberts; Sue L Heatley; Mignon L Loh; Marina Konopleva; I-Ming Chen; Olga Zimmermannova; Claire Schwab; Owen Smith; Marie-Joelle Mozziconacci; Christian Chabannon; Myungshin Kim; J H Frederik Falkenburg; Alice Norton; Karen Marshall; Oskar A Haas; Julia Starkova; Jan Stuchly; Stephen P Hunger; Deborah White; Charles G Mullighan; Cheryl L Willman; Jan Stary; Jan Trka; Jan Zuna
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

8.  Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review.

Authors:  Katya Gancheva; Andres Virchis; Julie Howard-Reeves; Nick Cp Cross; Diana Brazma; Colin Grace; Paul Kotzampaltiris; Fedra Partheniou; Elisabeth Nacheva
Journal:  Mol Cytogenet       Date:  2013-09-20       Impact factor: 2.009

9.  An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL.

Authors:  Purvi M Kakadia; Ralf Schmidmaier; Andreas Völkl; Irene Schneider; Natalia Huk; Stephanie Schneider; Gerda Panzner; Ulrike Neidel; Barbara Fritz; Karsten Spiekermann; Stefan K Bohlander
Journal:  Leuk Res Rep       Date:  2016-10-14

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.